Completed PHASE2 INTERVENTIONAL NCT00065533

Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer

Study of Two Doses of ALIMTA (Pemetrexed) as First Line Chemotherapy for Advanced Breast Cancer

Sponsor: Eli Lilly and Company

Interventions pemetrexed

Updated 7 times since 2017 Last updated: Jun 21, 2007 Started: May 31, 2003 Completion: Jun 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 7 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Badalona, Spain , Barcelona, Spain , Birmingham, United Kingdom , Brussels, Belgium , Bucharest, Romania , Buenos Aires, Argentina , Capitol Federal, Argentina , Cluj-Napoca, Romania , Leuven, Belgium , Madrid, Spain and 9 more locations